Answers are grounded in this paper and cite their sources.
Indole-3-carbinol (I3C) is a naturally occurring anticancer agent and has entered clinical trials for cancer prevention. However, the clinical development of I3C has been impeded by its poor metabolic profile. The active components of I3C were used to develop a novel class of indole analogs to optimize I3C's anticancer actions, including blocking growth factor-stimulated Akt activation. The most promising of these analogs, SR13668, exhibited potent oral anticancer activity against various cancers and no significant toxicity.
No takes yet. Share an insight, caveat, or question.
Chao et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: